Skip to content
MedsAcross

Medicine

Zolmitriptan OD 2.5 mg orally disintegrating tablet

Zolmitriptan · Oral · Jubilant Cadista Pharmaceuticals
Available on requestPrescription onlyUS FDAIndian manufacturer

Zolmitriptan OD 2.5 mg orally disintegrating tablet is a prescription medicine containing Zolmitriptan for oral use, marketed by Jubilant Cadista Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20ºC to 25°C (68ºF to 77ºF), excursions permitted to 15°C to 30°C…

Key facts

Active ingredient (INN)
Zolmitriptan
Brand
Zolmitriptan OD
Strength
2.5 mg
Dosage form
Orally disintegrating tablet
Route
Oral
Packs
2 blister pack
Marketing authorisation holder
Jubilant Cadista Pharmaceuticals
Manufacturers
Jubilant Cadista PharmaceuticalsIndiaAvKARE
Origin register
US FDA, United States
Storage
Store at 20ºC to 25°C (68ºF to 77ºF), excursions permitted to 15°C to 30°C (59ºF to 86ºF). Protect from light and moisture.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
N02CC03 Zolmitriptan
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
17 September 2015
Identifiers
RxCUI 284201, 351134DailyMed set ID a6a32fc6-4243-9cdd-91c7-b8a58e0f9811, 3f0040a6-b1d6-3d73-e063-6294a90af23cNDC 59746-461, 42291-998Application ANDA202956

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
2 blister pack in 1 carton / 3 tablet, orally disintegrating in 1 blister pack59746-461-16Jubilant Cadista PharmacuticalsIndia17 September 2015
2 blister pack in 1 carton / 3 tablet, orally disintegrating in 1 blister pack42291-998-06AvKARE17 September 2025

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 25 November 1997Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Zolmitriptan 2.5 mg orally disintegrating tablet.

Compare all 2

Other strengths and forms of Zolmitriptan

Clinical summary

Zolmitriptan is a serotonin-1b and serotonin-1d receptor agonist indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older, among other approved uses. MedsAcross supplies Zolmitriptan for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Zolmitriptan

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Zolmitriptan OD 2.5 mg orally disintegrating tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.